Literature DB >> 10447253

IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer.

T Hernandez-Boussard1, P Rodriguez-Tome, R Montesano, P Hainaut.   

Abstract

The tumor suppressor p53 gene is the most frequently mutated gene in human cancer. To date, more than 10,000 mutations have been described in the literature, and these data are available in various electronic formats on the World Wide Web. Here we describe the structure and format of the different p53 datasets maintained and curated at the International Agency for Research on Cancer (IARC) in Lyon, France. These include p53 somatic mutations (more than 10,000 entries), p53 germline mutations (144 entries), and p53 polymorphisms (13 entries), with the somatic mutations organized into a relational database using AccessTM. The main features of these datasets are (1) controlled entry with standardized format and restricted vocabulary, (2) inclusion of annotations on individual characteristics and exposures, and (3) a classification of pathologies based on the International Classification of Diseases for Oncology (ICD-O). In addition, several interfaces have been developed to analyze the data in order to produce mutation spectra, codon analyses, or visualization of the mutation with the tertiary structure of the protein. All datasets and tools for analysis are available at http://www.iarc.fr/p53/homepage.

Entities:  

Mesh:

Year:  1999        PMID: 10447253     DOI: 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1>3.0.CO;2-H

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  45 in total

1.  Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.

Authors:  G K Kovvali; B Mehta; C B Epstein; S G Lutzker
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

2.  Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Authors:  Min Lu; Xiaoli Wang; Yan Li; Joseph Tripodi; Goar Mosoyan; John Mascarenhas; Marina Kremyanskaya; Vesna Najfeld; Ronald Hoffman
Journal:  Blood       Date:  2012-08-07       Impact factor: 22.113

3.  Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA).

Authors:  H Dean Hosgood; Minsun Song; Chao Agnes Hsiung; Zhihua Yin; Xiao-Ou Shu; Zhaoming Wang; Nilanjan Chatterjee; Wei Zheng; Neil Caporaso; Laurie Burdette; Meredith Yeager; Sonja I Berndt; Maria Teresa Landi; Chien-Jen Chen; Gee-Chen Chang; Chin-Fu Hsiao; Ying-Huang Tsai; Li-Hsin Chien; Kuan-Yu Chen; Ming-Shyan Huang; Wu-Chou Su; Yuh-Min Chen; Chung-Hsing Chen; Tsung-Ying Yang; Chih-Liang Wang; Jen-Yu Hung; Chien-Chung Lin; Reury-Perng Perng; Chih-Yi Chen; Kun-Chieh Chen; Yao-Jen Li; Chong-Jen Yu; Yi-Song Chen; Ying-Hsiang Chen; Fang-Yu Tsai; Christopher Kim; Wei Jie Seow; Bryan A Bassig; Wei Wu; Peng Guan; Qincheng He; Yu-Tang Gao; Qiuyin Cai; Wong-Ho Chow; Yong-Bing Xiang; Dongxin Lin; Chen Wu; Yi-Long Wu; Min-Ho Shin; Yun-Chul Hong; Keitaro Matsuo; Kexin Chen; Maria Pik Wong; Dara Lu; Li Jin; Jiu-Cun Wang; Adeline Seow; Tangchun Wu; Hongbing Shen; Joseph F Fraumeni; Pan-Chyr Yang; I-Shou Chang; Baosen Zhou; Stephen J Chanock; Nathaniel Rothman; Qing Lan
Journal:  Hum Genet       Date:  2015-01-08       Impact factor: 4.132

4.  The DNA-binding domain mediates both nuclear and cytosolic functions of p53.

Authors:  Ariele Viacava Follis; Fabien Llambi; Li Ou; Katherine Baran; Douglas R Green; Richard W Kriwacki
Journal:  Nat Struct Mol Biol       Date:  2014-05-11       Impact factor: 15.369

5.  Genetic variation in the TP63 gene is associated with lung cancer risk in the Han population.

Authors:  Qun-Ying Hu; Tian-Bo Jin; Li Wang; Le Zhang; Tingting Geng; Guinian Liang; Long-Li Kang
Journal:  Tumour Biol       Date:  2013-10-04

6.  Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Authors:  Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

7.  Databases and QSAR for cancer research.

Authors:  Adeel Malik; Hemajit Singh; Munazah Andrabi; Syed Akhtar Husain; Shandar Ahmad
Journal:  Cancer Inform       Date:  2007-02-15

8.  Molecular characterization of p53 mutations in primary and secondary liver tumors: diagnostic and therapeutic perspectives.

Authors:  Apollonia Tullo; Elisabetta Sbisà
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

9.  Enhanced Expression of Radiation-induced Leukocyte CDKN1A mRNA in Multiple Primary Breast Cancer Patients: Potential New Marker of Cancer Susceptibility.

Authors:  Masato Mitsuhashi; David Peel; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Biomark Insights       Date:  2009-12-22

10.  Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.

Authors:  A Syed Sameer; Shakeel ul Rehman; Arshad A Pandith; Nidda Syeed; Zaffar A Shah; Nissar A Chowdhri; Khursheed A Wani; Mushtaq A Siddiqi
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.